Details of the Drug

General Information of Drug (ID: DMZGXUM)

Drug Name

Estazolam

Synonyms

Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

294.74

Logarithm of the Partition Coefficient (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability: 93% of drug becomes completely available to its intended biological destination(s) [3]
Elimination: 4% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 24 hours [4]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.097 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0015 mg/mL [2]

Chemical Identifiers

Formula: C16H11ClN4
IUPAC Name: 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Canonical SMILES: C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4
InChI: InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2
InChIKey: CDCHDCWJMGXXRH-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3261
ChEBI ID: CHEBI:4858
CAS Number: 29975-16-4
DrugBank ID: DB01215
TTD ID: D0P2CK
INTEDE ID: DR0633
ACDINA ID: D00245

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Agonist	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[8]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[8]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Estazolam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Estazolam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[9]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Estazolam and Oliceridine.	Acute pain [MG31]	[10]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Estazolam caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[11]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Estazolam caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Estazolam caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Estazolam caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[14]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Estazolam caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Estazolam caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[16]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Estazolam and Dihydrocodeine.	Chronic pain [MG30]	[17]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Estazolam caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[18]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Estazolam caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[19]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Estazolam and Esketamine.	Depression [6A70-6A7Z]	[20]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Estazolam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[9]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Estazolam caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Estazolam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Estazolam caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[23]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Estazolam caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[24]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Estazolam caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Estazolam caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Estazolam caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Estazolam caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Estazolam caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Estazolam caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Estazolam caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[31]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Estazolam caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[32]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Estazolam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[33]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Estazolam caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[34]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Estazolam caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[35]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Estazolam caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Estazolam caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Estazolam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[38]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Estazolam and Lasmiditan.	Migraine [8A80]	[39]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Estazolam caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[40]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Estazolam and Flibanserin.	Mood disorder [6A60-6E23]	[41]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Estazolam caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Estazolam caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[42]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Estazolam caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[43]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Estazolam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[44]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Estazolam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Estazolam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[45]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Estazolam caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[46]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Estazolam caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[47]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Estazolam and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[48]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Estazolam caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[49]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Estazolam caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[37]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Estazolam caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Minor	Increased metabolism of Estazolam caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[50]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Estazolam caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[51]
-----------


⏷ Show the Full List of 48 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Docusate sodium	E00563	23673837	Surfactant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Estazolam 2 mg tablet	2 mg	Oral Tablet	Oral
Estazolam 1 mg tablet	1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7550).
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9.
7	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65.
8	Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
9	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
10	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
12	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
13	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
14	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
15	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
17	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
18	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
19	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
20	Cerner Multum, Inc. "Australian Product Information.".
21	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
22	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
23	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
24	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
25	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
26	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
27	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
28	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
29	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
30	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
31	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
33	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
35	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
36	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
41	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
42	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
44	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
45	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
46	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
47	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
48	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
49	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
50	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
51	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.